Spots Global Cancer Trial Database for Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors
Official Title: A Phase I/IIa Study to Evaluate the Tolerance, Safety, Pharmacokinetic Characteristics and Preliminary Efficacy of PM1032 in Patients With Advanced Solid Tumors
Study ID: NCT05839106
Conditions
Interventions
Study Description
Brief Summary: The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of PM1032 for patients with advanced tumors, also to explore the recommended Phase Ⅱ Dose（RP2D） of PM1032.
Detailed Description: PM1032 is a Bispecific Antibody Targeting CLDN18.2 and 4-1BB.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Shulan (Hang Zhou) Hospital, Hangzhou, , China
The first affiliated hospital of nanchang university, Nanchang, , China
Shanghai Orient Hospital, Shanghai, , China
Contact Details
Name: Ye Guo
Affiliation: Shanghai Orient Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
